FISH

Fish Head Farms, Inc. Announces Distribution and Sales Agreement With AgroShield, LLC

Retrieved on: 
星期三, 五月 8, 2024
Agriculture, Natural Resources, Environment, Other Natural Resources, Forest Products, CFIA, Soybean, OMRI, FISH, USDA, Carbon, Farmer, Plant, CDFA, Soil, Nutrient, Marketing

Today, Fish Head Farms, Inc. is announcing a sales, marketing, and distribution agreement with AgroShield for FISH SH!T.

Key Points: 
  • Today, Fish Head Farms, Inc. is announcing a sales, marketing, and distribution agreement with AgroShield for FISH SH!T.
  • Fish Head Farms manufactures, markets, and distributes FISH SH!T, the most robust beneficial bacteria product available for use in the Agricultural, Golf Course Maintenance, Cannabis and Turf Industries.
  • The microbes in Fish Sh!t are designed to break down complex organic and synthetic matter and release essential nutrients into the soil.
  • Fish Sh!t improves germination rates, enhances root zones, and boosts nutrient availability, using an effective and ecologically safe approach.

Promising perspectives for the application of SDS Optic’s inPROBE technology platform for protein expression determination

Retrieved on: 
星期四, 四月 25, 2024
Breast cancer, SDS, Cancer, Fluorescence, HER2, Clinical trial, Immunohistochemistry, FISH, Patient, Research, Safety, IHC, Medical imaging

SDS Optic’s inPROBE® marks a pivotal shift in oncology towards personalized medicine, particularly in the assessment of protein expression like HER2.

Key Points: 
  • SDS Optic’s inPROBE® marks a pivotal shift in oncology towards personalized medicine, particularly in the assessment of protein expression like HER2.
  • This novel in vivo approach allows the examination with optic fiber probe directly in the patient’s body without tissue extraction.
  • These outcomes have paved the way for further research across different cancers and other diseases where protein markers are critical.
  • inPROBE® not only enhances the accuracy of cancer diagnostics and treatment but also holds potential for broader scientific and industrial applications.

Fish Head Farms, Inc. Announces Exclusive Distribution and Sales Agreement With Clesens

Retrieved on: 
星期四, 四月 11, 2024
Environment, Sports, Marketing, Golf, Communications, Fishing, Alternative Medicine, Health, Agriculture, Natural Resources, CFIA, OMRI, FISH, USDA, CDFA, NPK, Soil, Nutrient, Germination

Today, Fish Head Farms, Inc is announcing an exclusive sales, marketing, and distribution agreement with Clesens for FISH SH!T.

Key Points: 
  • Today, Fish Head Farms, Inc is announcing an exclusive sales, marketing, and distribution agreement with Clesens for FISH SH!T.
  • Fish Head Farms manufactures, markets, and distributes FISH SH!T, the most robust beneficial bacteria product available for use in the Agricultural, Golf Course Maintenance, Cannabis and Plant Industries.
  • The microbes in FISH SH!T are designed to break down complex organic and synthetic matter and release essential nutrients into the soil.
  • Joe Blanchard, Fish Head Farms Chief Revenue Officer, said, “As we continue to grow our distribution network nationally, in the Golf and Turf markets, we couldn’t be more excited to work with Clesens.

Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

Retrieved on: 
星期三, 四月 3, 2024
Sarcoma, Diagnosis, KT, Oncogene, SAN, Neoplasm, Research, Cancer, Doctor of Philosophy, CDKN2A, Workflow, Karyotype, FISH, Genomics, Chromothripsis, SVS, Prognosis, Aberration, OGM, Medical imaging

Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.

Key Points: 
  • Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.
  • The detection of SVs and CNVs remains challenging and typically requires multiple traditional cytogenetic techniques.
  • In this study, researchers demonstrated OGM’s ability to detect aberrations as small as 500 bp, which is approximately 10,000-fold higher resolution than that of KT.
  • As shown in this study, OGM can provide better characterization of the genomic complexity of sarcoma samples when compared to traditional cytogenetic techniques, due to the workflow’s high resolution and ​comprehensive, genome-wide analysis.

STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests

Retrieved on: 
星期二, 三月 26, 2024
Oncology, Health, FDA, Medical Devices, Clinical Trials, Pharmaceutical, Biotechnology, De novo, Stemcell Technologies, Plasma, In situ hybridization, Medicine, Cell, Bone marrow, Partnership, Risk, Patient, Fluorescence, Sale, Classification, Multiple myeloma, DSM-IV codes, B cell, IVD, National Comprehensive Cancer Network, American College, European, FISH, Cancer, CD138, Multimedia, Food, Medical device

STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.

Key Points: 
  • STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
  • View the full release here: https://www.businesswire.com/news/home/20240326396951/en/
    STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit is now classified by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
  • (Photo: Business Wire)
    The kit can be used to enrich plasma cells expressing the CD138 marker (CD138+ cells) from patient bone marrow samples.
  • The EasySep™ Human Bone Marrow CD138 Positive Selection Kit will be available for sale in the United States, the European Union, Canada, and the United Kingdom.

Fish Head Farms, Inc. Announces Exclusive Distribution and Sales Agreement With D&K Products, Inc.

Retrieved on: 
星期三, 三月 20, 2024
Environment, Sports, Marketing, Golf, Communications, Fishing, Alternative Medicine, Health, Agriculture, Natural Resources, USDA, OMRI, Nutrient, NPK, CDFA, Germination, FISH, Soil, CFIA

Today, Fish Head Farms, Inc is announcing an exclusive sales, marketing, and distribution agreement with D&K Products, Inc, for FISH SH!T.

Key Points: 
  • Today, Fish Head Farms, Inc is announcing an exclusive sales, marketing, and distribution agreement with D&K Products, Inc, for FISH SH!T.
  • The agreement between the companies is for the golf and turf markets in Iowa, Nebraska, and Western Illinois.
  • Fish Head Farms manufactures, markets, and distributes FISH SH!T, the most robust beneficial bacteria product available for use in the Agricultural, Golf Course Maintenance, Cannabis and Plant Industries.
  • Joe Blanchard, Fish Head Farms Chief Revenue Officer, said “We are thrilled to partner with D&K Products.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
星期二, 一月 30, 2024
SAN, Breast, University, International, MD Anderson Cancer Center, FACMG, FDA, VAF, Bone marrow, SVS, Cytogenetics, Genome, LRS, OGM, University of Toronto, TNBC, Pressure, Biomarker, PARP, Quality control, Karyotype, HRD, Saint John Regional Hospital, T-ALL, CRISPR, Curie Institute, Triple-negative breast cancer, In situ hybridization, FISH, Frog, Genomics, Hospital, HRP, Patient, Marfan syndrome, Fluorescence, NIST, DSM-IV codes, Doctor of Philosophy, Cancer, Multiple myeloma, Workflow, Gene editing, Research, KT, Cell, Down syndrome, NGS, Vaccine

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Retrieved on: 
星期三, 一月 24, 2024
SAN, Standard of care, Fluorescence, University of Rochester, Test management, University, SVS, FISH, Genomics, DSM-IV codes, In situ hybridization, IRB, SOC, Karyotype, CMA, KT, Columbia University, OGM, Clinical trial, Institutional review board, Data, Diagnosis, Medical device

This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.

Key Points: 
  • This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.
  • This second interim readout is designed to evaluate endpoints connected to analytical performance using an expanded dataset in key areas of technical performance and clinical utility of OGM.
  • The study is an Institutional Review Board (IRB)-approved, multicenter, double-blinded trial with samples from 219 unique retrospective (57) and prospective (162) clinical research subjects.
  • All samples had been previously tested with traditional methods including karyotyping (KT), fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA).

Molecular Diagnostics in Oncology, Genetic/Inherited Diseases and NIPT 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
星期一, 一月 29, 2024
Health, Oncology, ISH, NGS, DSM-IV codes, Research, Molecular diagnostics, IVD, Knowledge, NIPT, Cancer, Woman, Medicine, Risk, FISH, Recurrence, Laboratory, FDA, Biomarker, Diagnosis, PCR, Inherit, Segment, Chromosome, Gene expression, Medical imaging

The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • In addition, the fields of rare inherited/ genetic diseases and NIPT have become areas of new breakthroughs in healthcare.
  • These and other technologies and applications in oncology, rare inherited/ genetic disease, and NIPT molecular diagnostic testing are covered in the report.
  • The report contains detailed market data on the following IVD segments for their use in molecular testing:
    Molecular Diagnostics in Oncology Market by Segment, 2023-2028

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, Stomach, INN, Risk, HER2, Breast, Tissue, Heart, Cancer, Neoplasm, Cardiotoxicity, Infection, Anatomy, Paclitaxel, IIA, Breast cancer, ATC, European, Allergy, Metastasis, Blood, Capecitabine, MBC, EBC, Safety, Heart failure, MGC, Patient, Medical Subject Headings, Agency, European Commission, Cyclophosphamide, Immune system, Docetaxel, Carboplatin, International, Language, Cisplatin, Select, Enzyme inhibitor, Medicine, FISH, Radiation, Lymph, Arm, European Medicines Agency, Fluorouracil, Doxorubicin, Medical device

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised